应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
KYTX Kyverna Therapeutics
盘后交易 01-13 19:01:00 EST
8.66
+0.43
+5.22%
盘后
8.65
-0.01
-0.12%
18:38 EST
最高
8.70
最低
8.04
成交量
48.65万
今开
8.33
昨收
8.23
日振幅
8.02%
总市值
4.95亿
流通市值
2.88亿
总股本
5,713万
成交额
409.24万
换手率
1.46%
流通股本
3,330万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Kyverna Therapeutics, Inc.盘中异动 下午盘快速跳水5.06%报8.26美元
市场透视 · 01-09
Kyverna Therapeutics, Inc.盘中异动 下午盘快速跳水5.06%报8.26美元
新闻稿：Kyverna Therapeutics宣布拟进行普通股的公开发行
投资观察 · 2025-12-16
新闻稿：Kyverna Therapeutics宣布拟进行普通股的公开发行
Kyverna Therapeutics公布Miv-Cel (Kyv-101)在僵人综合征注册Kysa-8试验中的积极关键数据
美股速递 · 2025-12-15
Kyverna Therapeutics公布Miv-Cel (Kyv-101)在僵人综合征注册Kysa-8试验中的积极关键数据
Kyverna Therapeutics将发布Kyv-101在僵人综合症注册性第二阶段Kysa-8试验的顶线结果
美股速递 · 2025-12-15
Kyverna Therapeutics将发布Kyv-101在僵人综合症注册性第二阶段Kysa-8试验的顶线结果
Caribou Biosciences报告了关于同种异体CAR T疗法的临床数据，而Kyverna Therapeutics则推进了自身免疫项目Caribou Biosciences Reports Clinical Data on Allogeneic CAR T Therapies While Kyverna Therapeutics Advances Autoimmune Program
动脉网 · 2025-11-05
Caribou Biosciences报告了关于同种异体CAR T疗法的临床数据，而Kyverna Therapeutics则推进了自身免疫项目Caribou Biosciences Reports Clinical Data on Allogeneic CAR T Therapies While Kyverna Therapeutics Advances Autoimmune Program
Kyverna Therapeutics公司预计现金流可持续至2027年，支持其SPS的BLA申请及Mg三期临床试验
美股速递 · 2025-11-03
Kyverna Therapeutics公司预计现金流可持续至2027年，支持其SPS的BLA申请及Mg三期临床试验
Kyverna Therapeutics公布Kysa-6研究中Kyv-101在广泛性重症肌无力治疗中的积极一期2临床数据
美股速递 · 2025-10-29
Kyverna Therapeutics公布Kysa-6研究中Kyv-101在广泛性重症肌无力治疗中的积极一期2临床数据
Kyverna Therapeutics在2025年Acr Convergence会议上展示的1期研究数据强调了Kyv-101在类风湿性关节炎中的潜力
美股速递 · 2025-10-25
Kyverna Therapeutics在2025年Acr Convergence会议上展示的1期研究数据强调了Kyv-101在类风湿性关节炎中的潜力
Kyverna Therapeutics, Inc.盘中异动 股价大跌5.02%
市场透视 · 2025-10-24
Kyverna Therapeutics, Inc.盘中异动 股价大跌5.02%
Kyverna Therapeutics将在Ectrims会议上展示Kyv-101治疗多发性硬化症的1期研究者发起试验数据，凸显该药物潜力
美股速递 · 2025-09-24
Kyverna Therapeutics将在Ectrims会议上展示Kyv-101治疗多发性硬化症的1期研究者发起试验数据，凸显该药物潜力
Kyverna Therapeutics在虚拟专家会议上重点介绍神经免疫学CAR-T业务及重症肌无力注册性3期试验设计
美股速递 · 2025-08-28
Kyverna Therapeutics在虚拟专家会议上重点介绍神经免疫学CAR-T业务及重症肌无力注册性3期试验设计
Kyverna Therapeutics, Inc.盘中异动 股价大跌5.97%
市场透视 · 2025-07-29
Kyverna Therapeutics, Inc.盘中异动 股价大跌5.97%
Kyverna Therapeutics, Inc.盘中异动 早盘急速拉升5.48%
市场透视 · 2025-03-05
Kyverna Therapeutics, Inc.盘中异动 早盘急速拉升5.48%
Kyverna Therapeutics, Inc.盘中异动 股价大跌5.28%报2.69美元
市场透视 · 2025-03-03
Kyverna Therapeutics, Inc.盘中异动 股价大跌5.28%报2.69美元
Kyverna Therapeutics, Inc.盘中异动 早盘股价大跌5.17%报2.75美元
市场透视 · 2025-02-26
Kyverna Therapeutics, Inc.盘中异动 早盘股价大跌5.17%报2.75美元
Kyverna Therapeutics, Inc.盘中异动 股价大涨5.04%报2.92美元
市场透视 · 2025-02-25
Kyverna Therapeutics, Inc.盘中异动 股价大涨5.04%报2.92美元
Kyverna Therapeutics, Inc.盘中异动 早盘股价大涨5.45%报2.81美元
市场透视 · 2025-02-13
Kyverna Therapeutics, Inc.盘中异动 早盘股价大涨5.45%报2.81美元
Kyverna Therapeutics, Inc.盘中异动 早盘急速拉升6.04%报3.51美元
市场透视 · 2025-01-31
Kyverna Therapeutics, Inc.盘中异动 早盘急速拉升6.04%报3.51美元
Kyverna Therapeutics, Inc.盘中异动 股价大涨6.42%
市场透视 · 2025-01-30
Kyverna Therapeutics, Inc.盘中异动 股价大涨6.42%
Kyverna Therapeutics, Inc.盘中异动 快速跳水5.04%报3.39美元
市场透视 · 2025-01-30
Kyverna Therapeutics, Inc.盘中异动 快速跳水5.04%报3.39美元
加载更多
公司概况
公司名称：
Kyverna Therapeutics
所属市场：
NASDAQ
上市日期：
--
主营业务：
Kyverna Therapeutics, Inc.于2018年6月以BAIT Therapeutics, Inc.的名义在特拉华州注册成立，并于2019年10月更名为Kyverna Therapeutics, Inc.。该公司是一家以患者为中心的临床阶段生物制药公司，专注于为患有自身免疫性疾病的患者开发细胞疗法。该公司的目标是通过以患者为中心的方法、广阔的平台、治疗免疫疾病的洞察力以及细胞疗法在医学领域成功应用的经验教训，为患有自身免疫性疾病的患者带来改变疾病的治疗益处。
发行价格：
--
{"stockData":{"symbol":"KYTX","market":"US","secType":"STK","nameCN":"Kyverna Therapeutics","latestPrice":8.66,"timestamp":1768338000000,"preClose":8.23,"halted":0,"volume":486496,"hourTrading":{"tag":"盘后","latestPrice":8.65,"preClose":8.66,"latestTime":"18:38 EST","volume":2873,"amount":24864.487674,"timestamp":1768347491371},"delay":0,"floatShares":33297000,"shares":57129503,"eps":-3.72055,"marketStatus":"盘后交易","change":0.43,"latestTime":"01-13 19:01:00 EST","open":8.33,"high":8.7,"low":8.04,"amount":4092435.4877440003,"amplitude":0.080194,"askPrice":9.38,"askSize":100,"bidPrice":8.33,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.72055,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1768352400000},"marketStatusCode":4,"adr":0,"listingDate":1707368400000,"exchange":"NASDAQ","adjPreClose":8.23,"preHourTrading":{"tag":"盘前","latestPrice":8.278,"preClose":8.23,"latestTime":"09:15 EST","volume":469,"amount":3886.849694,"timestamp":1768313745597},"postHourTrading":{"tag":"盘后","latestPrice":8.65,"preClose":8.66,"latestTime":"18:38 EST","volume":2873,"amount":24864.487674,"timestamp":1768347491371},"volumeRatio":0.526082,"impliedVol":2.8293,"impliedVolPercentile":0.9004},"requestUrl":"/m/hq/s/KYTX","defaultTab":"news","newsList":[{"id":"2602720983","title":"Kyverna Therapeutics, Inc.盘中异动 下午盘快速跳水5.06%报8.26美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602720983","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602720983?lang=zh_cn&edition=full","pubTime":"2026-01-09 04:02","pubTimestamp":1767902551,"startTime":"0","endTime":"0","summary":"北京时间2026年01月09日04时02分，Kyverna Therapeutics, Inc.股票出现波动，股价大幅跳水5.06%。截至发稿，该股报8.26美元/股，成交量57.6845万股，换手率0.97%，振幅6.76%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为2.32%。其相关个股中，Enliven Therapeutics, Inc.、Century Therapeutics, Inc.、Moonlake Immunotherapeutics涨幅较大，Pmgc Holdings Inc.、Acrivon Therapeutics, Inc.、Gri Bio, Inc.较为活跃，换手率分别为527.89%、127.75%、81.83%，振幅较大的相关个股有Abpro Holdings Inc C/Wts 12/11/2029 、Enliven Therapeutics, Inc.、Briacell Therapeutics Corp C/Wts 26/02/2026，振幅分别为146.48%、59.43%、52.53%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109040232953c3d0e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109040232953c3d0e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4007","KYTX","BK4139","LENZ"],"gpt_icon":0},{"id":"1124946336","title":"新闻稿：Kyverna Therapeutics宣布拟进行普通股的公开发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1124946336","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124946336?lang=zh_cn&edition=full","pubTime":"2025-12-16 05:03","pubTimestamp":1765832595,"startTime":"0","endTime":"0","summary":"加利福尼亚州阿梅里维尔，2025年12月15日-- Kyverna Therapeutics, Inc.是一家专注于为自身免疫疾病患者开发细胞疗法的临床阶段生物制药公司，今天宣布已启动一项1亿美元的普通股承销公开发行。Kyverna打算给予承销商一个30天的选择权，以按照公开发行价格、扣除承销折扣和佣金的条件，额外购买最多1500万美元的普通股。所有将在拟议发行中出售的普通股均由Kyverna出售。J.P. Morgan、Leerink Partners、Morgan Stanley和Wells Fargo Securities作为该发行的联合簿记管理人。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1668664300.SGD","LU0234570918.USD","LU2023251221.USD","LU2089283258.USD","MS","IE00BKVL7J92.USD","LU1989772923.USD","BK4516","LU0006306889.USD","LU0557290698.USD","LU1732800096.USD","BK4504","LU1244550494.USD","LU0314104364.USD","LU1720051108.HKD","LU1791710400.SGD","LU1989772840.SGD","BK4585","LU2089284900.SGD","LU1162221912.USD","LU1791710582.SGD","LU1548497426.USD","BK4139","LU0106831901.USD","LU0320765646.SGD","BK4588","LU0158827948.USD","LU0098860793.USD","LU1732799900.SGD","LU0795875169.SGD","LU0106261372.USD","IE00BZ1G4Q59.USD","LU2271345857.HKD","LU0528227936.USD","BK4127","LU0158827781.USD","LU1244550221.USD","BK4581","LU2028103732.USD","LU0795875086.SGD","LU2111349929.HKD","LU2357305700.SGD","LU0971096721.USD","LU2133065610.SGD","KYTX","LU1720051017.SGD","LU0882574139.USD","LU1244550577.SGD","LU2347655156.SGD","LU0267386448.USD","LU1363072403.SGD","LU1074936037.SGD","LU0912757837.SGD","LU0225283273.USD","BK4534"],"gpt_icon":0},{"id":"1196824119","title":"Kyverna Therapeutics公布Miv-Cel (Kyv-101)在僵人综合征注册Kysa-8试验中的积极关键数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1196824119","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196824119?lang=zh_cn&edition=full","pubTime":"2025-12-15 19:30","pubTimestamp":1765798215,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics公布Miv-Cel (Kyv-101)在僵人综合征注册Kysa-8试验中的积极关键数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"1170285047","title":"Kyverna Therapeutics将发布Kyv-101在僵人综合症注册性第二阶段Kysa-8试验的顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1170285047","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170285047?lang=zh_cn&edition=full","pubTime":"2025-12-15 03:31","pubTimestamp":1765740676,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics将发布Kyv-101在僵人综合症注册性第二阶段Kysa-8试验的顶线结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2581779056","title":"Caribou Biosciences报告了关于同种异体CAR T疗法的临床数据，而Kyverna Therapeutics则推进了自身免疫项目Caribou Biosciences Reports Clinical Data on Allogeneic CAR T Therapies While Kyverna Therapeutics Advances Autoimmune Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2581779056","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581779056?lang=zh_cn&edition=full","pubTime":"2025-11-05 16:03","pubTimestamp":1762329780,"startTime":"0","endTime":"0","summary":"Caribou presented findings from trials involving its allogeneic CAR T therapies, which use donor-derived cells rather than a patient’s own cells. These therapies were tested in two separate cancer indications, though specific details regarding efficacy or safety outcomes were not disclosed in the report.Caribou公布了其同种异体CAR T疗法的试验结果，该疗法使用捐赠者来源的细胞而非患者自身的细胞。Meanwhile, Kyverna announced plans to move forward with its CAR T program aimed at treating autoimmune conditions. This marks a shift from the traditional focus of CAR T therapy on oncology and represents an effort to expand the technology’s applications into other therapeutic areas. Both companies continue to explore innovative approaches within this rapidly evolving sector of biotechnology..同时，Kyverna 宣布计划推进其旨在治疗自身免疫性疾病的 CAR T 项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110516052697554e2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110516052697554e2c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","KYTX","BK4139","CRBU","BK4022","CAR","LENZ","BK4539","BK4230"],"gpt_icon":0},{"id":"1180745023","title":"Kyverna Therapeutics公司预计现金流可持续至2027年，支持其SPS的BLA申请及Mg三期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1180745023","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180745023?lang=zh_cn&edition=full","pubTime":"2025-11-03 21:04","pubTimestamp":1762175058,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics公司预计现金流可持续至2027年，支持其SPS的BLA申请及Mg三期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"1166583441","title":"Kyverna Therapeutics公布Kysa-6研究中Kyv-101在广泛性重症肌无力治疗中的积极一期2临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1166583441","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166583441?lang=zh_cn&edition=full","pubTime":"2025-10-29 18:31","pubTimestamp":1761733875,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics公布了Kysa-6研究中Kyv-101在广泛性重症肌无力治疗中的积极一期2临床数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"1104181247","title":"Kyverna Therapeutics在2025年Acr Convergence会议上展示的1期研究数据强调了Kyv-101在类风湿性关节炎中的潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1104181247","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104181247?lang=zh_cn&edition=full","pubTime":"2025-10-25 23:00","pubTimestamp":1761404411,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics在2025年Acr Convergence会议上展示的1期研究数据强调了Kyv-101在类风湿性关节炎中的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"gpt_icon":0},{"id":"2577555165","title":"Kyverna Therapeutics, Inc.盘中异动 股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577555165","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577555165?lang=zh_cn&edition=full","pubTime":"2025-10-24 03:43","pubTimestamp":1761248631,"startTime":"0","endTime":"0","summary":"北京时间2025年10月24日03时43分，Kyverna Therapeutics, Inc.股票出现异动，股价急速跳水5.02%。截至发稿，该股报6.34美元/股，成交量22.1233万股，换手率0.51%，振幅9.86%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Ventyx Biosciences, Inc.、Neumora Therapeutics, Inc.、Reviva Pharmaceuticals Holdings, Inc.涨幅较大，Nls Pharmaceutics Ltd.、Ventyx Biosciences, Inc.、Ibio, Inc.较为活跃，换手率分别为173.11%、157.57%、140.46%，振幅较大的相关个股有Nls Pharmaceutics Ltd C/Wts 02/02/2026、Neumora Therapeutics, Inc.、Ibio, Inc.，振幅分别为93.32%、46.18%、38.85%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102403435194da3ddd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102403435194da3ddd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4007","KYTX","LENZ","BK4139"],"gpt_icon":0},{"id":"1182652575","title":"Kyverna Therapeutics将在Ectrims会议上展示Kyv-101治疗多发性硬化症的1期研究者发起试验数据，凸显该药物潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1182652575","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182652575?lang=zh_cn&edition=full","pubTime":"2025-09-24 21:06","pubTimestamp":1758719183,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics将在Ectrims会议上展示Kyv-101治疗多发性硬化症的1期研究者发起试验数据，凸显该药物潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"1105839120","title":"Kyverna Therapeutics在虚拟专家会议上重点介绍神经免疫学CAR-T业务及重症肌无力注册性3期试验设计","url":"https://stock-news.laohu8.com/highlight/detail?id=1105839120","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105839120?lang=zh_cn&edition=full","pubTime":"2025-08-28 20:01","pubTimestamp":1756382501,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics在虚拟专家会议上重点介绍神经免疫学CAR-T业务及重症肌无力注册性3期试验设计","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"gpt_icon":0},{"id":"2555522200","title":"Kyverna Therapeutics, Inc.盘中异动 股价大跌5.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555522200","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555522200?lang=zh_cn&edition=full","pubTime":"2025-07-29 22:13","pubTimestamp":1753798428,"startTime":"0","endTime":"0","summary":"北京时间2025年07月29日22时13分，Kyverna Therapeutics, Inc.股票出现异动，股价急速下挫5.97%。截至发稿，该股报4.07美元/股，成交量5.0998万股，换手率0.12%，振幅7.82%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.36%。其相关个股中，Salarius Pharmaceuticals, Inc.、Scinai Immunotherapeutics Ltd、Calidi Biotherapeutics, Inc.涨幅较大，Scinai Immunotherapeutics Ltd、Salarius Pharmaceuticals, Inc.、Tnf Pharmaceuticals, Inc.较为活跃，换手率分别为4115.08%、2496.21%、1402.23%，振幅较大的相关个股有Salarius Pharmaceuticals, Inc.、180 Life Sciences Corp C/Wts 07/11/2025、180 Life Sciences Corp.，振幅分别为111.98%、106.73%、75.60%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729221348a6c80331&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729221348a6c80331&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","KYTX","BK4539","BK4007"],"gpt_icon":0},{"id":"2517394880","title":"Kyverna Therapeutics, Inc.盘中异动 早盘急速拉升5.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517394880","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517394880?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:41","pubTimestamp":1741185660,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时41分，Kyverna Therapeutics, Inc.股票出现异动，股价急速拉升5.48%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.68%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Celularity Inc C/Wts 16/07/2026 涨幅较大，Silexion Therapeutics Corp、Tc Biopharm Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为414.92%、265.37%、199.22%，振幅较大的相关个股有Aditxt, Inc.、Silexion Therapeutics Corp、Tonix Pharmaceuticals Holding Corp.，振幅分别为23.90%、20.71%、19.74%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc 是一家临床阶段生物制药公司。其产品KYV-101是一种自体 CD19 CAR T细胞候选产品，由潜在的嵌合抗原受体制成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224100a260cad8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224100a260cad8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KYTX","LENZ","BK4139"],"gpt_icon":0},{"id":"2516663055","title":"Kyverna Therapeutics, Inc.盘中异动 股价大跌5.28%报2.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516663055","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516663055?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:06","pubTimestamp":1741014392,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时06分，Kyverna Therapeutics, Inc.股票出现波动，股价快速跳水5.28%。截至发稿，该股报2.69美元/股，成交量4.8885万股，换手率0.11%，振幅7.04%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Entero Therapeutics Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为1138.48%、126.15%、102.55%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Pliant Therapeutics, Inc.，振幅分别为163.15%、70.53%、48.34%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230632a25d4abf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230632a25d4abf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","KYTX"],"gpt_icon":0},{"id":"2514763011","title":"Kyverna Therapeutics, Inc.盘中异动 早盘股价大跌5.17%报2.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514763011","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514763011?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:29","pubTimestamp":1740500969,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时29分，Kyverna Therapeutics, Inc.股票出现波动，股价急速跳水5.17%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.34%。其相关个股中，Abpro Holdings Inc C/Wts 12/11/2029 、Silexion Therapeutics Corp、Conduit Pharmaceuticals Inc C/Wts 22/09/2028涨幅较大，Gt Biopharma, Inc.、Silexion Therapeutics Corp、Moleculin Biotech, Inc.较为活跃，换手率分别为1115.47%、909.65%、660.96%，振幅较大的相关个股有Silexion Therapeutics Corp、Abpro Holdings Inc C/Wts 12/11/2029 、Adial Pharmaceuticals, Inc，振幅分别为87.83%、66.67%、64.05%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022600293096300be9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022600293096300be9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KYTX","LENZ","BK4139"],"gpt_icon":0},{"id":"2514705993","title":"Kyverna Therapeutics, Inc.盘中异动 股价大涨5.04%报2.92美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514705993","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514705993?lang=zh_cn&edition=full","pubTime":"2025-02-25 04:47","pubTimestamp":1740430052,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日04时47分，Kyverna Therapeutics, Inc.股票出现波动，股价大幅上涨5.04%。截至发稿，该股报2.92美元/股，成交量23.5394万股，换手率0.55%，振幅8.57%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.31%。其相关个股中，Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 涨幅较大，Pepgen Inc.、Aditxt, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为331.77%、144.98%、41.60%，振幅较大的相关个股有Nutriband Inc C/Wts 、Pepgen Inc.、Surrozen Inc C/Wts 01/08/2031 ，振幅分别为176.22%、164.23%、81.92%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225044732a25262e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225044732a25262e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","KYTX","BK4139"],"gpt_icon":0},{"id":"2511452573","title":"Kyverna Therapeutics, Inc.盘中异动 早盘股价大涨5.45%报2.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511452573","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511452573?lang=zh_cn&edition=full","pubTime":"2025-02-13 22:39","pubTimestamp":1739457553,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日22时39分，Kyverna Therapeutics, Inc.股票出现异动，股价大幅上涨5.45%。截至发稿，该股报2.81美元/股，成交量7694股，换手率0.02%，振幅3.95%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.33%。其相关个股中，Edesa Biotech, Inc.、Moleculin Biotech, Inc.、Dominari Holdings Inc.涨幅较大，Tc Biopharm Plc、Edesa Biotech, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为1018.35%、955.48%、163.64%，振幅较大的相关个股有Moleculin Biotech, Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 、Edesa Biotech, Inc.，振幅分别为56.19%、32.86%、30.10%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502132239139621bde7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502132239139621bde7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KYTX","BK4139","LENZ"],"gpt_icon":0},{"id":"2507961596","title":"Kyverna Therapeutics, Inc.盘中异动 早盘急速拉升6.04%报3.51美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507961596","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507961596?lang=zh_cn&edition=full","pubTime":"2025-01-31 23:18","pubTimestamp":1738336715,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日23时18分，Kyverna Therapeutics, Inc.股票出现波动，股价大幅拉升6.04%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.29%。其相关个股中，Nls Pharmaceutics Ltd C/Wts 02/02/2026、Cyclerion Therapeutics, Inc.、Nls Pharmaceutics Ltd.涨幅较大，Nls Pharmaceutics Ltd.、Cyclerion Therapeutics, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1773.35%、1633.77%、122.38%，振幅较大的相关个股有Nls Pharmaceutics Ltd C/Wts 02/02/2026、Cyclerion Therapeutics, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为63.20%、56.30%、46.27%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501312318359877654c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501312318359877654c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","KYTX"],"gpt_icon":0},{"id":"2507262163","title":"Kyverna Therapeutics, Inc.盘中异动 股价大涨6.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507262163","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507262163?lang=zh_cn&edition=full","pubTime":"2025-01-30 22:33","pubTimestamp":1738247588,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日22时33分，Kyverna Therapeutics, Inc.股票出现异动，股价快速拉升6.42%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Tectonic Therapeutic, Inc.、Alterity Therapeutics Limited、Kazia Therapeutics Limited涨幅较大，Kazia Therapeutics Limited、Alterity Therapeutics Limited、Silexion Therapeutics Corp较为活跃，换手率分别为605.75%、125.00%、103.30%，振幅较大的相关个股有Tectonic Therapeutic, Inc.、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Alterity Therapeutics Limited，振幅分别为21.38%、21.31%、18.28%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025013022330896143dae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025013022330896143dae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","KYTX"],"gpt_icon":0},{"id":"2507265168","title":"Kyverna Therapeutics, Inc.盘中异动 快速跳水5.04%报3.39美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507265168","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507265168?lang=zh_cn&edition=full","pubTime":"2025-01-30 01:52","pubTimestamp":1738173155,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日01时52分，Kyverna Therapeutics, Inc.股票出现波动，股价快速下挫5.04%。Kyverna Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.20%。其相关个股中，Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Silexion Therapeutics Corp、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大，Silexion Therapeutics Corp、60 Degrees Pharmaceuticals, Inc.、Vincerx Pharma, Inc.较为活跃，换手率分别为5565.89%、2279.09%、757.75%，振幅较大的相关个股有Ocean Biomedical Inc C/Wts 14/02/2028 、Ocean Biomedical, Inc.、Protagenic Therapeutics Inc C/Wts 29/04/2026 ，振幅分别为185.36%、95.88%、95.00%。Kyverna Therapeutics, Inc.公司简介：Kyverna Therapeutics Inc 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130015235abbc7d92&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130015235abbc7d92&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KYTX","LENZ","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://kyvernatx.com","stockEarnings":[{"period":"1week","weight":0.0123},{"period":"1month","weight":-0.0626},{"period":"3month","weight":0.2175},{"period":"6month","weight":1.0221},{"period":"1year","weight":1.3855},{"period":"ytd","weight":-0.1245}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kyverna Therapeutics, Inc.于2018年6月以BAIT Therapeutics, Inc.的名义在特拉华州注册成立，并于2019年10月更名为Kyverna Therapeutics, Inc.。该公司是一家以患者为中心的临床阶段生物制药公司，专注于为患有自身免疫性疾病的患者开发细胞疗法。该公司的目标是通过以患者为中心的方法、广阔的平台、治疗免疫疾病的洞察力以及细胞疗法在医学领域成功应用的经验教训，为患有自身免疫性疾病的患者带来改变疾病的治疗益处。","exchange":"NASDAQ","name":"Kyverna Therapeutics","nameEN":"Kyverna Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kyverna Therapeutics(KYTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kyverna Therapeutics(KYTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kyverna Therapeutics,KYTX,Kyverna Therapeutics股票,Kyverna Therapeutics股票老虎,Kyverna Therapeutics股票老虎国际,Kyverna Therapeutics行情,Kyverna Therapeutics股票行情,Kyverna Therapeutics股价,Kyverna Therapeutics股市,Kyverna Therapeutics股票价格,Kyverna Therapeutics股票交易,Kyverna Therapeutics股票购买,Kyverna Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kyverna Therapeutics(KYTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kyverna Therapeutics(KYTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}